BCR-ABL expression in leukemic progenitors and primitive stem cells of patients with chronic myeloid leukemia

Blood

Volumn 119, Issue 12, 2012, Pages 2964-2965

  Chomel, Jean Claude ^a   Sorel, Nathalie ^a   Guilhot, Joëlle ^a   Guilhot, François ^b   Turhan, Ali G ^a  

^a POITIERS UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ DE POITIERS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BCR ABL PROTEIN; IMATINIB; MESSENGER RNA; PROTEIN TYROSINE KINASE INHIBITOR;

CANCER STEM CELL; CHRONIC MYELOID LEUKEMIA; DRUG WITHDRAWAL; HUMAN; LETTER; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STEM CELL;

EID: 84858835938     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-12-396226     Document Type: Letter

References (8)

1. Kumari A, Brendel C, Hochhaus A, Neubauer A, Burchert A. Low BCR-ABL expression levels in hematopoietic precursor cells enable persistence of chronic myeloid leukemia under imatinib. Blood. 2012;119(2):530-539.
2. Chomel JC, Sorel N, Bonnet ML et al. Extensive analysis of the T315I substitution and detection of additional ABL mutations in progenitors and primitive stem cell compartment in a patient with tyrosine kinase inhibitor-resistant chronic myeloid leukemia. Leuk Lymphoma. 2010;51(11):2103-2111.
3. Chomel JC, Bonnet ML, Sorel N et al. Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease. Blood. 2011;118(13):3657-3660.
4. Chu S, McDonald T, Lin A et al. Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment. Blood. 2011;118(20):5565-5572.
5. Graham SM, Jorgensen HG, Allan E et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood. 2002;99(1):319-325.
6. Jiang X, Zhao Y, Smith C et al. Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies. Leukemia. 2007;21(5):926-935. (Pubitemid 46672068)
7. Bedi A, Zehnbauer BA, Collector MI et al. BCR-ABL gene rearrangement and expression of primitive hematopoietic progenitors in chronic myeloid leukemia. Blood. 1993;81(11):2898-2902. (Pubitemid 23162107)
8. Keating A, Wang XH, Laraya P. Variable transcription of BCR-ABL by Ph+ cells arising from hematopoietic progenitors in chronic myeloid leukemia. Blood. 1994;83(7):1744-1749. (Pubitemid 24107895)